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235 The CF couch potato! Habitual physical activity in an adult
CF population
S. Howard1, R. Mills-Bennett1, D. Lau1, R.I. Ketchell1, J. Duckers1. 1All Wales
Adult Cystic Fibrosis Centre (AWACFC), University Hospital Llandough, Penarth,
United Kingdom
Background: Physical activity has been shown as beneﬁcial to CF. Patients health
and quality of life are positively affected by physical training (Wilkes 2009).
Increased habitual physical activity (HPA) has been shown to reduce the speed
of lung function decline. Physical inactivity signiﬁcantly contributes to exercise
intolerance and skeletal muscle weakness in CF (Troosters 2009).
Objectives: To compare the HPA of stable adult outpatient CF patients with
recognised ranges in other chronic diseases.
Method: 10 patients wore the Sensewear® electronic activity monitors. Demo-
graphic and anthropometric data were collected.
Results: 10 patients (8 male) participated with mean (SD) age, FEV1%, BMI and
FFMI of 28.3 years (8.1), 54.2% (19.8), 22.1 kg/m2 (2.0) and 17.9 kg/m2 (1.8)
respectively. Patients wore the Sensewear® for a mean (SD) 6.5 days (4.4) and the
mean (SD) percentage time on body was 91.6% (8.9). Their mean (SD) shuttle-walk
test was 491.4m (202.4). Their mean (SD) Metabolic Equivalents (METS) activity
during the monitored period was 1.7 (0.18) with patients spending a mean (SD)
time of 200 minutes (71) engaged in activity greater than 3 METS. The mean (SD)
number of steps taken per day was 4552 (2475).
Conclusion: The mean METS per day equates to very low activity levels such
as knitting with patients only spending around 3 hours doing activities equating to
light activity such as playing pool which is considered inadequate for cardiovascular
conditioning (Jette 1990). The average steps per day are below those considered
normal for people living with chronic disability/disease (range 7000–9000) (Tudor-
Locke 2011).
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Non-compliance with immunosuppressive drug therapy is a signiﬁcant risk factor
for graft loss. Administration of the once-daily tacrolimus (tac) extended-release
formulation (ADV) instead of the conventional twice-daily formulation (PRO) might
improve compliance. The objectives of our study were to obtain pharmacokinetic
(PK) data in stable lung transplant (LTx) recipients converted from PRO to ADV
and to compare PK data obtained with ADV in non-CF and CF LTx recipients.
Nineteen patients (9 CF) were studied. PRO PK proﬁles were collected on 3
consecutive days. Patients were then switched to ADV on a 1:1.1mg basis and ADV
PK proﬁles were collected at steady-state on 3 consecutive days. Tac exposure over
24 hrs was computed as the area under the concentration-time curve (AUC0−24h)
for ADV and as the AUC0−12h x 2 for PRO. The AUC was determined by Bayesian
estimation, using a one-compartment PK model with ﬁrst-order elimination and the
absorption phase described by a double gamma distribution. Mean tac exposure was
compared between subjects and formulations using 2-way ANOVA. In non-CF LTx
recipients the mean PRO and ADV dose was 2.3±1.5mg BID and 5.0±3.1mg QD;
there was no difference in mean tac exposure between PRO and ADV (244±56
vs. 246±76 h.mg/L, p = 0.722). In CF LTx recipients the mean PRO and ADV
dose was 3.3±1.6mg BID and 7.2±3.8mg QD; mean tac exposure with PRO
was marginally superior to ADV (287±60 vs 275±37 h.mg/L, p = 0.019) with this
conversion ratio. PRO and ADV provided similar mean tac exposures in non-CF
and CF LTx recipients. These encouraging results should be conﬁrmed in a larger
patient sample.
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237 Thrush − a lesser spotted resident in the CF service?
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Aim: Patients with CF are at increased risk of Candida infection due to long term
antibiotics, diabetes and inhaled/oral steroids. Due to the relatively benign nature
of orogenital Candidal infection it is often not seen as a priority by CF teams and
often not discussed but it may cause signiﬁcant morbidity to CF patients.
Method: 136 questionnaires were given out to sequential patients attending the
AWACFC over a three month period. These were completed anonymously and
explored how frequently patients suffered from symptoms consistent with oral or
genital thrush, whether they received treatment from the AWACFC for thrush and if
they were asked about symptoms routinely and if they felt comfortable discussing
symptoms with the team.
Results: 110 (57 females) questionnaires were returned (81% response rate). 62
(35 females) of the 110 (56%) reported having had recurrent symptoms of oral
Candida. 57 (35 females) of the 110 (52%) reported recurrent symptoms of genital
Candida. Only 44% of patients with oral symptoms and 28% with symptoms of
genital Candida ever had treatment from the AWACFC. Others purchased over the
counter treatments or sought advice from their General Practitioner. 40 of the 110
patients (36%) ever recalled being asked by a member of the team about symptoms
of thrush. Only 18 (16%) felt uncomfortable discussing symptoms with a member
of the AWACFC.
Conclusion: Recurrent symptoms of orogenital Candida infection appeared to be
common in our patients yet most patients self medicated or sought treatment from
their GP. As a team we do not regularly enquire about symptoms despite most of
our patients being comfortable discussing symptoms with us.
238 Medication reconciliation in Wales − a problem shared
B. Richards1, M. Lea-Davies1, L. Speight1, D. Lau1, R.I. Ketchell1, J. Duckers1.
1All Wales Adult Cystic Fibrosis Centre (AWACFC), University Hospital Llandough,
Penarth, United Kingdom
Aim: Cystic Fibrosis Trust Standards of Care Guidelines promote the provision
of “prescription monitoring and medication review services” within specialist
centres [1]. We reviewed the effectiveness of medication reconciliation taking place
amongst patients registered at the AWACFC in 2013.
Method: For each patient registered at the AWACFC the most recent medication
script issued by the GP was compared with contemporaneous medication lists
from AWACFC medical notes. This allowed discrepancies to be identiﬁed between
prescribing of 16 key CF medications at the interface of care between AWACFC
and GP.
Results: Of the 226 patients attending the AWACFC 216 patients had prescription
records available from the GP. Of these 216 patients (118 male) the mean age,
FEV1% and BMI were 27.9 years (SD 9.4), 64.8% (SD 24.1) and 23.1 kg/m
2
(SD 4.5) respectively. 165 of the 216 (76%) patients were found to have at least
one medication reconciliation error on their prescription, including omission, com-
mission, dosing and frequency errors. The most accurately reconciled medication
was Creon 159/168 (95%). Hypertonic saline was found to have the highest rate
of non-reconciliation with 25% of patients originally prescribed the medication not
receiving the medication as intended.
Conclusion: With increasingly complex and expensive treatment regimes adding
to treatment burden and affecting adherence it is clear that medicine reconciliation
service provision needs to be more thoroughly addressed. Many records were found
to have prescribing discrepencies and we need to identify the reasons for these
and take steps to remedy them and improve communication between primary and
secondary care.
